EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access

Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti–HIV-1 Antibodies

Marie Høst Pahus, Yu Zheng, Maxine Olefsky, Jesper Damsgaard Gunst, Pablo Tebas iD, Babafemi Taiwo, Ole S Søgaard, Michael J Peluso, Yolanda Lie, Jacqueline D Reeves, Christos J Petropoulos, Marina Caskey und 1 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae486 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Marie Høst Pahus und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Aarhus University Hospital, Denmark. Hauptthemen laut MEDLINE: HIV Antibodies, Antibodies, Neutralizing, HIV-1, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Development of a screening assay for the clinical use of broadly neutralizing antibodies (bnAbs) is a priority for HIV therapy and cure initiatives.

Methods

We assessed the PhenoSense Monoclonal Antibody Assay (Labcorp-Monogram Biosciences), which is Clinical Laboratory Improvement Amendments (CLIA) validated and has been used prospectively and retrospectively in multiple recent bnAb clinical trials.

Results

When performed on plasma and longitudinal peripheral blood mononuclear cell samples (before and during antiretroviral therapy, respectively), as sourced from a recent clinical trial, the PhenoSense assay produced robust reproducibility, concordance across sample types, and expected ranges in the susceptibility measures of bnAbs in clinical development. When applied retrospectively to baseline samples from 3 recent studies, the PhenoSense assay correlated with published laboratory-based study evaluations, but baseline bnAb susceptibility was not consistently predictive of durable virus suppression. Assessment of assay feasibility in 4 recent clinical studies provides estimates of assay success rate and processing time.

Conclusions

The PhenoSense Monoclonal Antibody Assay provides reproducible bnAb susceptibility measurements across relevant sample types yet is not consistently predictive of virus suppression. Logistical and operational assay requirements can affect timely clinical trial conduct. These results inform bnAb studies in development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV AntibodiesAntibodies, NeutralizingHIV-1HIV InfectionsNeutralization TestsHumansReproducibility of ResultsRetrospective StudiesLeukocytes, MononuclearAntibodies, Monoclonal

Stichwörter der Autor:innen

HIVbroadly neutralizing antibodiesclinical trialsscreening assays

Substanzen

HIV AntibodiesAntibodies, NeutralizingAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Infectious Diseases, Aarhus University Hospital, Denmark.
  • Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Division of Infectious Disease, Department of Medicine, University of Pennsylvania, Philadelphia.
  • Division of Infectious Disease, Department of Medicine, Northwestern University, Chicago, Illinois.
  • Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California San Francisco.
  • Labcorp-Monogram Biosciences, South San Francisco, California.

ORCID-Profile: Pablo Tebas, Katharine J Bar

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • Lundbeck Foundation
  • Penn CFAR
  • BEAT-HIV Delaney
  • Statistical and Data Management Center
  • National Institutes of Health

Zitieren

APA

Pahus, M. H., Zheng, Y., Olefsky, M., Gunst, J. D., Tebas, P., Taiwo, B., Søgaard, O. S., Peluso, M. J., Lie, Y., Reeves, J. D., Petropoulos, C. J., Caskey, M., & Bar, K. J. (2025). Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti–HIV-1 Antibodies. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae486

Vancouver

Pahus MH, Zheng Y, Olefsky M, Gunst JD, Tebas P, Taiwo B, et al. Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti–HIV-1 Antibodies. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae486

BibTeX
@article{Pahus2025,
  author = {Pahus, Marie Høst and Zheng, Yu and Olefsky, Maxine and Gunst, Jesper Damsgaard and Tebas, Pablo and Taiwo, Babafemi and Søgaard, Ole S and Peluso, Michael J and Lie, Yolanda and Reeves, Jacqueline D and Petropoulos, Christos J and Caskey, Marina and Bar, Katharine J},
  title = {Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti–HIV-1 Antibodies},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae486}
}
Kostenlos starten →